According to the researchers: “Treatment with thymosin beta 4 resulted in increased re-epithelialization and considerable capillary in-growth. Vessel counts showed a significant increase in the number of vessels in the thymosin beta 4 treated wounds. We also observed an increase in the deposition/accumulation of collagen in the thymosin beta 4-treated wounds.”
Dr Gabriel Sosne, whose research team has conducted the corneal research on thymosin beta 4 and who is a member of RegeneRx’s medical and scientific advisory board, said: “The data supporting the use of thymosin beta 4 as a wound healing and anti-inflammatory agent continues to accumulate, confirmed by independent researchers throughout the world in ophthalmic, dermal and cardiovascular tissues.”